Atlas Trials

Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

Clinical trial NCT03707847 · UNKNOWN

Trial details

NCT number
NCT03707847
Sponsor
Mingzhi Zhang
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
ALK-Positive Anaplastic Large Cell Lymphoma
Start date
2018-10-01
Primary completion
2020-02-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.